Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23654424 | 0.80 | HTT (0.37) | ITGAVITGB6ALDH1A1SMN1; SMN2CETP | |
| SCHEMBL20221227 | 0.79 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL20931295 | 0.78 | ALDH1A1 (0.44) | DGAT1ALDH1A1SMN1; SMN2CETPP2RX7 | |
| SCHEMBL13954119 | 0.76 | ALDH1A1 (0.32) | ITGAVITGB6ALDH1A1SMN1; SMN2 | |
| SCHEMBL16369860 | 0.76 | FFAR3 (0.48) | ITGAVITGB6ALDH1A1SMN1; SMN2CETP | |
| SCHEMBL19372578 | 0.76 | ALDH1A1 (0.47) | DGAT1ALDH1A1SMN1; SMN2CETPP2RX7 | |
| SCHEMBL19372576 | 0.76 | ALDH1A1 (0.47) | DGAT1ALDH1A1SMN1; SMN2CETPP2RX7 | |
| SCHEMBL23623428 | 0.76 | ALDH1A1 (0.47) | DGAT1ALDH1A1SMN1; SMN2CETPP2RX7 | |
| SCHEMBL7879549 | 0.76 | ALDH1A1 (0.47) | DGAT1ALDH1A1SMN1; SMN2CETPP2RX7 | |
| SCHEMBL2556815 | 0.76 | NPSR1 (0.37) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| WO-2019055750-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | DGAT1 4454/4885ITGAV 4810/4885ITGB6 4719/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | DGAT1 4454/4885ITGAV 4810/4885ITGB6 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.